First half of 2024: Boehringer Ingelheim progresses
Milestones reached in cardiovascular, renal, metabolic health (CRM), and oncologyFurther data read-outs expected in 2024 in oncology, mental health, and ...
Read moreMilestones reached in cardiovascular, renal, metabolic health (CRM), and oncologyFurther data read-outs expected in 2024 in oncology, mental health, and ...
Read moreGerman Vice Chancellor and Federal Minister of Economics Robert Habeck inaugurates new biomass power plantIngelheim site can cover 95% of ...
Read moreBoehringer Ingelheim and OSE Immunotherapeutics advance clinical development of first-in-class SIRP cancer immunology treatment BI 770371 Ingelheim, Germany and ...
Read moreNews builds on previously announced primary endpoint, which showed up to 83.0% of adults achieved statistically significant improvement in metabolic ...
Read moreCompany announcement - No. 30 / 2024 Zealand Pharma announces that Boehringer Ingelheim’s survodutide demonstrates breakthrough improvement in liver fibrosis ...
Read moreHuman Pharma sales up 10.3%* to EUR 20.8 bn, driven by JARDIANCE® and OFEV®Animal Health sales up 6.9 %* to ...
Read moreSingle-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to ...
Read moreBoehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced a further expansion and upgrade of its plant in Koropi, Greece. ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.